Key Highlights

  • Patent Milestone: The USPTO issued a Notice of Allowance for US Patent Application No. 19/669,218 covering oral tablet forms of elraglusib.
  • Clinical Readiness: A Phase 1/2 trial of the oral tablet formulation is planned for the first quarter of 2027.
  • Immune Response Mechanism: Sustained oral dosing is expected to affect CD8+ and NK cell activity, potentially enhancing anti-tumor immune responses.
  • IP Portfolio Expansion: The allowance adds protection for the oral dosage form to the company's existing portfolio around elraglusib.

Actuate Therapeutics, Inc.(NASDAQ:ACTU), a clinical-stage biopharmaceutical company, announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering oral tablet forms of its lead drug candidate, elraglusib. The company plans to file the patent following standard USPTO procedures, advancing intellectual property protection for the formulation it intends to study in a Phase 1/2 clinical trial beginning in early 2027.

The Science Behind the Oral Formulation

Elraglusib works by inhibiting GSK-3β, an enzyme involved in tumor growth, resistance to chemotherapy, and regulation of immune checkpoints. Until now, the drug has been administered intravenously on weekly or twice-weekly schedules across several studies in patients with refractory and resistant cancers in both adults and children. The oral tablet formulation is designed to allow daily dosing, which the company expects would produce more consistent drug levels in the bloodstream.

Pre-clinical and clinical analysis has identified specific plasma concentrations of elraglusib that correlate with observed clinical benefits and changes in tumor size. The company's preclinical data suggest that maintaining sustained drug exposure — rather than the peaks and valleys associated with intermittent IV dosing — produces distinct effects on immune cells within the tumor environment. Observed changes include increased recruitment of CD8+ T cells and natural killer cells, along with reductions in immune suppressive features that can help tumors evade immune detection.

What the Patent Covers and Why It Matters

The allowed patent claims cover the composition of the oral tablet dosage form itself, including the optimized formulation Actuate has developed for upcoming trials. Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics, said that daily oral administration offers greater dosing flexibility and patient convenience compared to intravenous infusions, while also creating new possibilities for studying elraglusib in maintenance therapy and combination treatment settings.

Andrew Mazar, Chief Operating Officer of Actuate Therapeutics, characterized the patent allowance as a meaningful step in protecting the company's Investment in the oral formulation ahead of clinical trials. Intellectual property protection at this stage is particularly relevant because Phase 1/2 trials generate data that could attract Partnership interest or inform regulatory discussions, and having composition claims in place before that data exists strengthens the company's negotiating position.

Risks

Clinical-stage companies face the recurring challenge that early-stage results, including the preclinical and clinical data that motivated the oral tablet development, do not reliably predict outcomes in later trials. The Phase 1/2 trial will be the first time the oral formulation is tested systematically in humans, and results could differ from what the preclinical exposure-effect models suggest. The company has also disclosed that access to additional Capital will be needed to complete the Phase 1/2 trial and advance toward registration-enabling studies.

What to Watch Next

The Phase 1/2 trial of Elraglusib Oral Tablet is expected to begin in the first quarter of 2027, with the primary objectives of evaluating safety, tolerability, and pharmacokinetics, alongside early signals of anti-tumor activity. Initial enrollment and any interim safety readouts from that trial will be the next key data points. The company has also indicated that maintaining or entering into additional financing arrangements will be necessary as the program advances.

Sector Context

The broader oncology Drug Development space has seen growing interest in formulation improvements that preserve a drug's mechanism while improving how it is delivered. Oral versions of drugs previously given intravenously have historically faced both clinical and regulatory scrutiny around whether plasma exposure equivalence translates to equivalent efficacy, particularly in oncology where dosing precision can be critical. Actuate's approach of using preclinical exposure-effect data to define target plasma levels in advance of the oral trial reflects a methodology that regulators and clinical partners increasingly expect.